BIMZELX effective for moderate to severe plaque psoriasis treatment

UCB has revealed results from its Phase III/IIIb trials of BIMZELX (bimekizumab) for the treatment of adults with moderate to severe plaque psoriasis. The data were presented at the 2022 AAD Annual Meeting which ran from March 25th to today, the 29th.

Data from the trials showed that more than eight out of ten patients (80%) who achieved complete skin clearance with bimekizumab at week 16, and entered open-label extension, maintained this response through two years.

Bimekizumab is a humanised monoclonal IgG1 antibody that is designed to selectively and directly inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

“Long term complete skin clearance is an important goal for people with psoriasis, and the new 96-week data from the open-label extension period of the BE RADIANT study offer fresh insights on the sustained response and clinical potential of bimekizumab in moderate to severe plaque psoriasis,” said Bruce Strober, MD, PhD, Clinical Professor, Department of Dermatology, Yale University School of Medicine, New Haven, CT, U.S., and Central Connecticut Dermatology Research, Cromwell, CT, US. “In addition, the improved clinical responses seen in patients who switched to bimekizumab after 48 weeks of treatment with secukinumab offer further new insights that should help to inform future clinical practice.”

Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of US, UCB, added: “We are pleased to share our latest long-term data on bimekizumab with the dermatology community at the 2022 AAD Annual Meeting. The wealth of new data, insights and progress being presented underlines our commitment to advances in psoriasis care for people living with this challenging, life-long condition.”

Lina Adams